{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:04:22Z","timestamp":1782903862804,"version":"3.54.5"},"reference-count":77,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["RC 2022"],"award-info":[{"award-number":["RC 2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Artificial intelligence (AI), a field of research in which computers are applied to mimic humans, is continuously expanding and influencing many aspects of our lives. From electric cars to search motors, AI helps us manage our daily lives by simplifying functions and activities that would be more complex otherwise. Even in the medical field, and specifically in oncology, many studies in recent years have highlighted the possible helping role that AI could play in clinical and therapeutic patient management. In specific contexts, clinical decisions are supported by \u201cintelligent\u201d machines and the development of specific softwares that assist the specialist in the management of the oncology patient. Melanoma, a highly heterogeneous disease influenced by several genetic and environmental factors, to date is still difficult to manage clinically in its advanced stages. Therapies often fail, due to the establishment of intrinsic or secondary resistance, making clinical decisions complex. In this sense, although much work still needs to be conducted, numerous evidence shows that AI (through the processing of large available data) could positively influence the management of the patient with advanced melanoma, helping the clinician in the most favorable therapeutic choice and avoiding unnecessary treatments that are sure to fail. In this review, the most recent applications of AI in melanoma will be described, focusing especially on the possible finding of this field in the management of drug treatments.<\/jats:p>","DOI":"10.3390\/cells11243965","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T02:17:57Z","timestamp":1670465877000},"page":"3965","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Artificial Intelligence and Advanced Melanoma: Treatment Management Implications"],"prefix":"10.3390","volume":"11","author":[{"given":"Antonino","family":"Guerrisi","sequence":"first","affiliation":[{"name":"Radiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2796-0792","authenticated-orcid":false,"given":"Italia","family":"Falcone","sequence":"additional","affiliation":[{"name":"SAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1098-7705","authenticated-orcid":false,"given":"Fabio","family":"Valenti","sequence":"additional","affiliation":[{"name":"UOC Oncological Translational Research, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5149-757X","authenticated-orcid":false,"given":"Marco","family":"Rao","sequence":"additional","affiliation":[{"name":"Enea-FSN-TECFIS-APAM, C.R. Frascati, via Enrico Fermi, 45, 00146 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-4071","authenticated-orcid":false,"given":"Enzo","family":"Gallo","sequence":"additional","affiliation":[{"name":"Pathology Unit, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-958X","authenticated-orcid":false,"given":"Sara","family":"Ungania","sequence":"additional","affiliation":[{"name":"Medical Physics and Expert Systems Laboratory, Department of Research and Advanced Technologies, IRCCS-Regina Elena Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-9126","authenticated-orcid":false,"given":"Maria Teresa","family":"Maccallini","sequence":"additional","affiliation":[{"name":"Departement of Clinical and Molecular Medicine, Universit\u00e0 La Sapienza di Roma, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fanciulli","sequence":"additional","affiliation":[{"name":"SAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Frascione","sequence":"additional","affiliation":[{"name":"Oncologic and Preventative Dermatology, IFO-San Gallicano Dermatological Institute-IRCCS, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Morrone","sequence":"additional","affiliation":[{"name":"Scientific Direction, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Caterino","sequence":"additional","affiliation":[{"name":"Radiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Valenti, F., Falcone, I., Ungania, S., Desiderio, F., Giacomini, P., Bazzichetto, C., Conciatori, F., Gallo, E., Cognetti, F., and Ciliberto, G. (2021). Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083837"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8427042","DOI":"10.1155\/2019\/8427042","article-title":"Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery","volume":"2019","author":"Nagarajan","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fmed.2020.00233","article-title":"Artificial Intelligence in Skin Cancer Diagnostics: The Patients\u2019 Perspective","volume":"7","author":"Jutzi","year":"2020","journal-title":"Front. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/annonc\/mdy166","article-title":"Man against machine: Diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists","volume":"29","author":"Haenssle","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature21056","article-title":"Dermatologist-level classification of skin cancer with deep neural networks","volume":"542","author":"Esteva","year":"2017","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., and Milella, M. (2020). Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12102870"},{"key":"ref_7","first-page":"23","article-title":"The role of tumor microenvironment in development and progression of malignant melanomas\u2014A systematic review","volume":"59","author":"Gurzu","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","article-title":"Intratumor and Intertumor Heterogeneity in Melanoma","volume":"10","author":"Grzywa","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Savoia, P., Fava, P., Casoni, F., and Cremona, O. (2019). Targeting the ERK Signaling Pathway in Melanoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061483"},{"key":"ref_11","first-page":"1071","article-title":"Cutaneous melanoma: From pathogenesis to therapy (Review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0076-6879(07)00403-X","article-title":"Inducible BRAF suppression models for melanoma tumorigenesis","volume":"439","author":"Hoeflich","year":"2008","journal-title":"Methods Enzymol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1089\/ten.tea.2018.0210","article-title":"3D Coculture Models Underline Metastatic Melanoma Cell Sensitivity to Vemurafenib","volume":"25","author":"Morales","year":"2019","journal-title":"Tissue Eng. Part A"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","article-title":"Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma","volume":"23","author":"Delord","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13046-018-0820-5","article-title":"Therapeutic potential of combined BRAF\/MEK blockade in BRAF-wild type preclinical tumor models","volume":"37","author":"Conciatori","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/17512433.2019.1570847","article-title":"Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations","volume":"12","author":"Trojaniello","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14712598.2018.1420777","article-title":"Ipilimumab for the treatment of metastatic prostate cancer","volume":"18","author":"Alaia","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4103\/jcrt.JCRT_1290_16","article-title":"Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma","volume":"14","author":"Koppolu","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The Next Immune-Checkpoint Inhibitors: PD-1\/PD-L1 Blockade in Melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/CCM.0000000000003685","article-title":"Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)","volume":"47","author":"Hotchkiss","year":"2019","journal-title":"Crit. Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/cts.13127","article-title":"Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)","volume":"15","author":"Wu","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1007\/s12325-021-01796-6","article-title":"Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review","volume":"38","author":"Arru","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/21645515.2018.1551671","article-title":"Product review: Avelumab, an anti-PD-L1 antibody","volume":"15","author":"Collins","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_28","first-page":"61","article-title":"Immunotherapy of melanoma","volume":"22","author":"Lugowska","year":"2018","journal-title":"Contemp. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5152\/eurasianjmed.2018.18194","article-title":"Immunological Agents Used in Cancer Treatment","volume":"51","author":"Simsek","year":"2019","journal-title":"Eurasian J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E4223","DOI":"10.1073\/pnas.1617941114","article-title":"Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab","volume":"114","author":"Ramagopal","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ejca.2015.08.012","article-title":"Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab","volume":"51","author":"Eroglu","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_34","first-page":"2481","article-title":"PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract","volume":"19","author":"Akiyama","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1158\/1078-0432.CCR-16-1821","article-title":"PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison","volume":"23","author":"Sunshine","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/mmt-2017-0018","article-title":"Anti-PD-1 and PD-L1 antibodies in metastatic melanoma","volume":"4","author":"Simeone","year":"2017","journal-title":"Melanoma Manag."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2019.01.016","article-title":"High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells","volume":"447","author":"Liang","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lu, A., and Zhang, G. (2016). A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1\/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071151"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2019.12.007","article-title":"Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges","volume":"471","author":"Huang","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/ajim.23037","article-title":"Artificial intelligence: Implications for the future of work","volume":"62","author":"Howard","year":"2019","journal-title":"Am. J. Ind. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13645706.2019.1575882","article-title":"Introduction to artificial intelligence in medicine","volume":"28","author":"Mintz","year":"2019","journal-title":"Minim. Invasive Ther. Allied Technol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.mri.2019.12.006","article-title":"Artificial intelligence in medical imaging","volume":"68","author":"Gore","year":"2020","journal-title":"Magn. Reson. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s11030-021-10217-3","article-title":"Artificial intelligence to deep learning: Machine intelligence approach for drug discovery","volume":"25","author":"Gupta","year":"2021","journal-title":"Mol. Divers."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1200\/CCI.20.00072","article-title":"Machine Learning in Oncology: Methods, Applications, and Challenges","volume":"4","author":"Bertsimas","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1148\/radiol.2018171820","article-title":"Current Applications and Future Impact of Machine Learning in Radiology","volume":"288","author":"Choy","year":"2018","journal-title":"Radiology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2217\/pgs-2018-0008","article-title":"Deep learning in pharmacogenomics: From gene regulation to patient stratification","volume":"19","author":"Kalinin","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-3-030-16391-4_11","article-title":"Artificial Intelligence and Personalized Medicine","volume":"178","author":"Schork","year":"2019","journal-title":"Cancer Treat. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/j.gastro.2020.04.062","article-title":"Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial","volume":"159","author":"Repici","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5946\/ce.2020.082","article-title":"Artificial Intelligence in Lower Gastrointestinal Endoscopy: The Current Status and Future Perspective","volume":"54","author":"Milluzzo","year":"2021","journal-title":"Clin. Endosc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1148\/radiol.2019182627","article-title":"Artificial Intelligence for Mammography and Digital Breast Tomosynthesis: Current Concepts and Future Perspectives","volume":"293","author":"Geras","year":"2019","journal-title":"Radiology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fpsyt.2018.00290","article-title":"A Deep Learning Approach for Predicting Antidepressant Response in Major Depression Using Clinical and Genetic Biomarkers","volume":"9","author":"Lin","year":"2018","journal-title":"Front. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"704607","DOI":"10.3389\/fonc.2021.704607","article-title":"Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach","volume":"11","author":"Guerrisi","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/cts.12884","article-title":"Precision Medicine, AI, and the Future of Personalized Health Care","volume":"14","author":"Johnson","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1002\/cncr.25261","article-title":"BRAF, a target in melanoma: Implications for solid tumor drug development","volume":"116","author":"Flaherty","year":"2010","journal-title":"Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"20190948","DOI":"10.1259\/bjr.20190948","article-title":"Radiomics: From qualitative to quantitative imaging","volume":"93","author":"Rogers","year":"2020","journal-title":"Br. J. Radiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"W283","DOI":"10.2214\/AJR.15.14315","article-title":"Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis","volume":"205","author":"Smith","year":"2015","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1007\/s00330-018-5933-x","article-title":"Metastatic melanoma: Pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab","volume":"29","author":"Durot","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/neuonc\/noz141","article-title":"MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors","volume":"21","author":"Bhatia","year":"2019","journal-title":"Neuro Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","article-title":"Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition","volume":"26","author":"Basler","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gill, A.B., Rundo, L., Wan, J.C.M., Lau, D., Zawaideh, J.P., Woitek, R., Zaccagna, F., Beer, L., Gale, D., and Sala, E. (2020). Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12123493"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Park, Y., Heider, D., and Hauschild, A.C. (2021). Integrative Analysis of Next-Generation Sequencing for Next-Generation Cancer Research toward Artificial Intelligence. Cancers, 13.","DOI":"10.3390\/cancers13133148"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"035002","DOI":"10.1088\/2057-1739\/2\/3\/035002","article-title":"The prisoner\u2019s dilemma as a cancer model","volume":"2","author":"West","year":"2016","journal-title":"Converg. Sci. Phys. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bayer, P., Gatenby, R.A., McDonald, P.H., Duckett, D.R., Stankova, K., and Brown, J.S. (2022). Coordination games in cancer. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0261578"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/1078-0432.CCR-20-4092","article-title":"The State of Melanoma: Emergent Challenges and Opportunities","volume":"27","author":"Atkins","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e14071","DOI":"10.1200\/JCO.2020.38.15_suppl.e14071","article-title":"The RIC-Mel Network. Machine learning models to predict the response to anti-cancer therapy in metastatic melanoma patients","volume":"38","author":"EMaubec","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1038\/s41598-020-63821-y","article-title":"Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis","volume":"10","author":"Shofty","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1878-0261.12732","article-title":"Serum markers improve current prediction of metastasis development in early-stage melanoma patients: A machine learning-based study","volume":"14","author":"Mancuso","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1078-0432.CCR-20-2415","article-title":"Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma","volume":"27","author":"Johannet","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cpt.1724","article-title":"A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma","volume":"107","author":"Wang","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaoncol.2021.6818","article-title":"Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis","volume":"8","author":"Dercle","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5694\/mja2.50759","article-title":"Use of artificial intelligence in skin cancer diagnosis and management","volume":"213","author":"Wada","year":"2020","journal-title":"Med. J. Aust."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e25759","DOI":"10.2196\/25759","article-title":"Role of Artificial Intelligence Applications in Real-Life Clinical Practice: Systematic Review","volume":"23","author":"Yin","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-021-01633-1","article-title":"Artificial intelligence in oncology: Current applications and future perspectives","volume":"126","author":"Luchini","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"FSO787","DOI":"10.2144\/fsoa-2021-0074","article-title":"An overview of artificial intelligence in oncology","volume":"8","author":"Farina","year":"2022","journal-title":"Future Sci. OA"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/24\/3965\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:36:12Z","timestamp":1760146572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/24\/3965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":77,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cells11243965"],"URL":"https:\/\/doi.org\/10.3390\/cells11243965","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]}}}